Top Stock Reports for Oracle, T-Mobile & Gilead

Thursday, March 12, 2026

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Oracle Corp. (ORCL), T-Mobile US, Inc. (TMUS) and Gilead Sciences, Inc. (GILD), as well as two micro-cap stocks National Research Corp. (NRC) and C&F Financial Corp. (CFFI). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.

These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Ahead of Wall Street

The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.

You can read today's AWS here >>> Jobless Claims, Housing Starts Improve. Pre-Markets Still Down

Today's Featured Research Reports

Oracle’s shares have outperformed the Zacks Computer - Software industry over the past year (+11.6% vs. +2.7%). The company reported solid fiscal 3Q’26 results, wherein earnings and revenues beat estimates. Oracle’s cloud infrastructure revenues surged 84% fueled by strong AI workload and multicloud demand, supported by strategic partnerships and competitive pricing that attract enterprise workload migrations.

Free cash flow for the trailing 12 months was negative $13.2 billion as Oracle continues aggressive investments in data center build-outs to support accelerating cloud and AI demand.

However, competition from hyperscalers remains intense, potentially pressuring margins. The ongoing transition from license revenue to subscription models creates near-term earnings volatility. Fiscal 2026 guidance indicates continued cloud acceleration, but execution risks around data center capacity expansion warrant monitoring.

(You can read the full research report on Oracle here >>>)

Shares of T-Mobile have underperformed the Zacks Wireless National industry over the past six months (-10.1% vs. -1.6%). Owing to the company’s premium valuation, the Zacks analyst believes investors should remain cautious as macroeconomic factors, market saturation, or economic downturns can significantly impact overvalued stocks like TMUS. Fierce competition in the U.S. wireless market is straining profitability. The high debt burden remains a major concern.

Nevertheless, T-Mobile is benefiting from industry-leading postpaid customer growth with a record-low churn rate. Its acquisition strategy has significantly strengthened its position in the wireless industry over the past few years.

TMUS’ 2.5 GHz 5G spectrum delivers superfast speeds and extensive coverage with signals that go through walls and trees. This boosts its competitive edge against companies that provide 5G networks controlled by the mmWave spectrum. Its focus on efficient capital management is a positive.

(You can read the full research report on T-Mobile here >>>)

Gilead’s shares have outperformed the Zacks Medical - Biomedical and Genetics industry over the past six months (+30.6% vs. +19.5%). The company’s fourth-quarter results were better than expected. Gilead boasts a market-leading HIV franchise. Biktarvy for treatment and Descovy for pre-exposure prophylaxis (PrEP) have fueled GILD’s top-line growth over the past several quarters.

Gilead now expects HIV sales to grow approximately 6% in 2026. The Zacks analyst sales estimates for Biktarvy indicate a CAGR of around 6% over the next three years. Gilead's HIV portfolio received a boost with the approval of its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, for PrEP.

Gilead is also developing additional HIV treatments, which, if approved, should strengthen the franchise. Gilead's efforts to bolster its oncology and virology franchises through collaborations are impressive. However, the Cell therapy franchise is facing challenges.

(You can read the full research report on Gilead here >>>)

Shares of National Research have outperformed the Zacks Business - Information Services industry over the past six months (+0.5% vs. -15.2%). This microcap company with a market capitalization of $362.74 million has seen its Total Recurring Contract Value (TRCV), the key leading metric, have risen for five consecutive quarters, reaching a record ~$152 by March 2026, signaling potential revenue conversion in upcoming periods.

Commercial execution also appears to be improving, with new sales up ~86% in 2025 following a sales reorganization and retention reaching its highest level in more than seven years. NRC’s large installed base — serving over 250 of the top 400 U.S. healthcare systems — supports cross-sell opportunities across its expanding platform.

However, revenues have declined for three consecutive years and margins compressed in 2025, creating execution risk if TRCV fails to translate into growth. Additional risks include customer concentration, healthcare spending cycles and competition from larger analytics providers. The stock trades below industry valuation benchmarks.

(You can read the full research report on National Research here >>>)

C&F Financial’s shares have outperformed the Zacks Banks - Southeast industry over the past six months (+1.5% vs. -5.3%). This microcap company with market capitalization of $232.33 million, benefits from a diversified three-segment model that supports more stable earnings through cycles and reduces reliance on any single revenue stream. Core banking expansion continues to drive recurring income as loan and deposit growth strengthen the balance sheet and support interest income generation.

Mortgage banking performance is improving as originations recover and fee-based servicing activity expands, helping diversify revenue beyond traditional gain-on-sale dynamics. Consumer finance remains profitable while shifting toward higher-yielding, core auto lending with disciplined underwriting.

Strong internal capital generation supports steady book value growth, dividends, and share repurchase flexibility. Key risks include margin pressure from interest-rate shifts, rising operating expenses and uncertainty around the durability of certain deposit inflows.

(You can read the full research report on C&F Financial here >>>)

Other noteworthy reports we are featuring today include Analog Devices, Inc. (ADI), EOG Resources, Inc. (EOG) and Fidelity National Information Services, Inc. (FIS).

Mark Vickery
Senior Editor

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>

Today's Must Read

Oracle (ORCL) Gains from Cloud Suite Adoption and Partnerships

T-Mobile (TMUS) Rides on Strong Demand for Postpaid Services

HIV Franchise Fuel Gilead (GILD) Amid Oncology Challenges

Featured Reports

EOG Resources (EOG) Poised for Growth on Premium Shale Assets
The Zacks analyst believes EOG is well positioned for strong production growth and consistent returns with more than 12 billion boe in multi-basin resources and highly productive shale acreage.

Fidelity National (FIS) Solid on Top-Line Growth, Buyouts
Per the Zacks analyst, strong performance of the company's Banking Solutions segment is driving revenues. Acquisitions continue to boost its presence across several regions.

Clean Harbors (CLH) Gains From Recurring Revenues Amid High Completion
Per the Zacks Analyst, Clean Harbors' expertise in hazardous waste disposal and long-term service contracts ensures recurring revenues. Rising competition from other players is an overhang.

Strength in Industrial Segment Aids Graco (GGG), Costs Hurt
Per the Zacks analyst, solid traction of Graco's Industrial segment, led by solid demand for liquid finishing systems should drive its growth. However, high operating costs remain concerning.

Regency (REG) to Grow on Buyouts and Strong Tenant Roster Amid High De
Per the Zacks Analyst, Regency's recent buyouts will aid long-term growth. Strong tenant roster drives dependable traffic and generates steady revenues. Yet, e-commerce adoption and debt burden ails.

Investments Aid OGE Energy (OGR) Amid Supply Chain Issues
Per the Zacks analyst, OGE Energy makes systematic investments to maintain and upgrade the reliability of its infrastructure. Yet supply chain issues result in delays and increase costs.

Bath and Body Works (BBWI) Gains on Digital Strength and Loyalty
Per the Zacks analyst, Bath and Body Works benefits from digital enhancements, strong loyalty engagement and higher average order values, boosting customer spending and omnichannel performance.

New Upgrades

Analog Devices (ADI) Rides on Traction in BMS Solutions
Per the Zacks analyst, Analog Devices is benefiting from a strong momentum in the electric vehicle space on the back of its robust Battery Management System solutions.

MKS (MKSI) Rides on AI-related Semiconductor Demand and NAND Upgrades
Per the Zacks analyst, MKS is benefiting from the growing demand in the Semiconductor and Electronics and Packaging markets, particularly in AI-related applications and NAND upgrades.

Animal Health and Vaccines Growth Lift Phibro (PAHC) Outlook
Per the Zacks analyst, strong demand for animal health products and vaccines, expansion of the MFA line and rising traction in nutritional specialties are expected to support Phibro's growth outlook.

New Downgrades

Elevated Costs, Capital Markets Dependence to Hurt Jefferies (JEF)
Per the Zacks analyst, rising costs due to technology-related spend will hurt Jefferies' profits. The volatile nature of the capital markets business might make growth in trading revenues difficult.

Housing Weakness and Macro Risks are Hurting Vulcan's (VMC) Growth
Per the Zacks analyst, Vulcan's prospects are pulling back due to a weak residential market because of affordability challenges. Also, macro and weather-related risks add to the headwinds.

Yield Pressure and Macro Woes Hurt Norwegian Cruise's (NCLH) Prospects
Per the Zacks analyst, Norwegian Cruise faces yield pressure from Caribbean deployment missteps and softer booking trends. Macro uncertainty and high costs remain concerns.

Zacks Names #1 Semiconductor Stock

This under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be.

With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028.

See This Stock Now for Free >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Analog Devices, Inc. (ADI): Free Stock Analysis Report

Gilead Sciences, Inc. (GILD): Free Stock Analysis Report

Fidelity National Information Services, Inc. (FIS): Free Stock Analysis Report

EOG Resources, Inc. (EOG): Free Stock Analysis Report

Oracle Corporation (ORCL): Free Stock Analysis Report

T-Mobile US, Inc. (TMUS): Free Stock Analysis Report

C&F Financial Corporation (CFFI): Free Stock Analysis Report

National Research Corporation (NRC): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research